Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The microtubule plus end is one of the two distinct ends of a microtubule, characterized by exposed β-tubulin subunits. It exhibits dynamic instability, alternating between phases of growth, pause, and shrinkage. The plus end is crucial for various cellular processes, including cell division, motility, and intracellular transport, and is regulated by plus-end tracking proteins (+TIPs) like EB1/EB3 and CLIP170. Disruption of plus-end dynamics is implicated in diseases like cancer and neurodevelopmental disorders. Microtubule plus ends are a target for cancer therapy.
Taxanes stabilize microtubules, preventing depolymerization. Colchicine and vinca alkaloids bind to tubulin dimers and prevent polymerization.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Microtubule Plus End (MT +end).